AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...

MedImmune Inc., the Gaithersburg-based pharmaceutical known for its nasal influenza vaccine FluMist, has completed its acquisition of Cellective Therapeutics Inc.<@SM><@SM><TAB>MedImmune ...

MedImmune’s other approved drug is CytoGam, which generated $20.3 million in sales last year. It prevents a viral infection common after kidney transplantation.

MedImmune Inc. said yesterday it will buy a California biotechnology firm for about $1.5 billion in stock, an acquisition that adds an experimental nasal-spray flu vaccine to the Gaithersburg ...

After 16 years of guiding MedImmune Inc. from a struggling Gaithersburg biotech to one of the world’s most profitable, Chief Executive David M. Mott is stepping down for personal reasons, the ...

GAITHERSBURG, Md. MedImmune Ventures, an investment group and subsidiary of AstraZeneca, has pitched in with five other groups for a $49.3 million investment into Ambit, a San Diego cancer drug ...

MedImmune Inc. on Monday agreed to buy vaccine maker Aviron in a bid to add FluMist, Aviron's promising treatment for influenza, to its own portfolio of drugs for infectious diseases.

MedImmune, now the Gaithersburg subsidiary of the London-based AstraZeneca PLC, is using the funding to produce and test the flu-fighting technology it uses in its seasonal FluMist product for ...

MedImmune was first to market with a swine flu vaccine in 2009. This year, it won approval for the first intranasal flu vaccine that contains four strains of the disease. Most vaccines contain three.

SAN FRANCISCO (MarketWatch) -- MedImmune Inc. late Monday said its first-quarter profit more than tripled over the same period last year, helped by lower costs and a 15% surge in revenue.